CytoGenix Scientists to Publish Book Chapter.HOUSTON -- CytoGenix, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYGX) announced today that its Vice President and Chief Scientific Officer, Dr. Yin Chen and Senior Scientist, Dr. Xin-Xing Tan were invited by Nova Science Publishers, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of to contribute a chapter for a soon to be published text titled "New Research on Antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). Elements (Genetics)". Dr. Chen's and Dr. Tan's contribution entitled "Oligodeoxynucleotide Expression Library for Discovery of Novel Antibiotics" is a review of the results of their work in the development of DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. compounds that are highly effective against antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. resistant strains. Traditionally, most antibacterial drugs come from bacteria, fungi or other natural sources. Through natural selection, resistant strains of bacteria have developed protection mechanisms against the activity of these natural substances. Drs. Chen's and Tan's research demonstrates how genetics can be used to find gene targets that are less subject to change as the basis for developing novel DNA antimicrobial compounds. Dr. Malcolm Skolnick, CytoGenix CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. commented, "CytoGenix is home to a cadre of scientists with skill and training in molecular and cell biology, nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. chemistry and infectious diseases. This multidiscipline group has invented two innovative platform technologies and continues to investigate new product opportunities. The work reported by Drs. Yin and Tan forms the basis for an important approach to combating antibiotic resistant bacteria." About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix is the recipient of the 2006 Frost & Sullivan Technology Innovation award for biotechnology processing, and has one issued US patent and 43 international or US pending patent applications claiming methods and materials in connection with these platform technologies. SAFE HARBOR Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion